Introduction: Traumatic brain injury (TBI) is a leading cause of death and disability worldwide.
Introduction
Traumatic brain injury (TBI) is a leading cause of death and disability, especially among children and young adults, causing long-term devastating effects on the survivors and their families and posing huge costs to society. Each year more than 50 million TBIs occur worldwide with an estimated overall cost of approximately US$400 billion -0.5% of the entire annual global output [1] . Despite these already staggering figures, according to the World Health Organization, TBI is projected to become the third leading contributor to the disease burden by 2020.
TBI is a highly heterogeneous disease, and the types of injury and recovery patterns are significantly influenced by the cause of the injury. The trauma produces the initial injury, disrupting the structural integrity of the brain, destroying tissue, and causing vascular and parenchymal damage, intracerebral hemorrhage, and axonal shearing. However, the damage to the brain surpass the initial insult, a complex cascade of biochemical and cellular events associated with secondary injury, that include disruption of the blood-brain barrier (BBB), inflammation, excessive neural excitability, and oxidative stress, is initiated [2, 3] . These processes persist for months to years post-injury, perhaps lifelong, eliciting both regenerative and degenerative tissue response [3] .
Because of the heterogeneous and chronic/evolving nature of TBI, the serious consequences and adverse outcome, and the significant challenges to identify definitive effective interventions, objective indicators of the different pathogenic processes that can be used for diagnosis, prognostication, and better stratification and characterization of patients, and to help optimize management and therapeutic pathways, are a priority research area [1, 4] .
Despite the tremendous efforts has been devoted and a number of promising acute and subacute/chronic markers have been identified [5] [6] [7] [8] , currently, while implemented regionally [9] , no blood-based markers are routinely adopted worldwide in clinical practice [6, 10] and the quest for novel more accurate and refined TBI biomarker is still ongoing.
This review focuses on a novel promising family of biomarkers, namely extracellular vesicles.
We discuss emerging approaches and currently available evidence from experimental and human studies, highlighting their potentials to sort out patient variability and develop and guide targeted personalized, even preemptive, therapies towards precision medicine practice. Importantly, gaps and challenges which may hamper and hold back successful translation to bedside are outlined.
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Extracellular vesicles
Extracellular vesicles (EVs) represent a heterogeneous group of membrane vesicles of less than 1μm in diameter released into the extracellular environment from virtually all cell types (e.g., platelets, lymphocytes, astrocytes, fibroblasts, endothelium and neuronal cells etc.). They serve as carriers of many bioactive molecules including cytosolic proteins, nucleic acids (mRNA, miRNA), and lipids, and have been demonstrated to play a critical role in intercellular communication, [11, 12] permitting, among others, the acquisition of new functional properties by recipient cells [13] .
Despite EVs can be physiologically found in healthy individuals, data from many studies clearly show that their production increase during cell activation, oxidative stress, tissue hypoxia, and in other various pathological conditions [14] .
Based upon the mechanism formation and the intracellular site origin (endosomal or cell membrane), size, markers, and contents EV can be divided into exosomes, microparticles (MPs), also called microvesicles (MVs), and apoptotic bodies.
Exosomes are small vesicles with a diameter of 30-100 nm originated from specialized compartment of the endosomal-lysosomal pathway and stored as intraluminal vesicles inside multivesicular bodies. Exosomes are constitutively or selectively released depending on the cell type [13] . Johnstone in 1987 first described exosomes as extracellularly intraendosomal vesicles released during the maturation process of reticulocytes. Importantly, the signature biomarkers expressed/contained on exosome membrane permit to track their original cell and determine the cells they will interact with [15, 16] . In addition, they have a lipid bilayer structure that allows them to get through the BBB easily and confers relative stability and protection from degradation in the blood and CSF [17] . These features make them particularly suitable as candidate biomarkers of brain damages and dynamic pathophysiological processes associated with TBI, and as vehicles for delivering therapeutic molecules.
MPs/MVs are, on the other hand, irregularly shaped phospholipid vesicles with a diameter of 100-1000nm, formed by cell-membrane budding/blebbing triggered by various activation stimuli that lead to increased intracellular calcium levels [14, 18] . Like exosomes, MPs can be derived from different cell types and their protein and lipid composition is indicative of their cellular origin [19] . Furthermore, as their production in brain cells is enhanced as a result of tissue damage A c c e p t e d M a n u s c r i p t and ischemic and inflammatory insults, they can provide crucial information on cell injury and/or underlying pathophysiological mechanisms.
Apoptotic bodies are another form of membrane vesicles which bud directly from the plasma membrane upon programmed cell death. They are heterogeneous in size (800-5000 nm) and morphology and may contain nuclear fragments, including histones [20, 21] .
A major ongoing challenge is to establish methods that allow to accurately separate the populations of membrane vesicles. Thus, despite attempts that have been made to characterize EV subtypes, in many studies investigators did not make clear-cut distinctions, and the terms 'MPs/MVs' or 'exosomes' indicate a heterogeneous mixture of different types and populations of cell-derived vesicles. In this review, we retained the definition used by the original authors.
Extracellular vesicles and TBI
There is now substantial evidence that EVs can originate from cells of the nervous system, In TBI, assessment of levels and temporal profiles of EVs in biofluids as well as the characterization of their different phenotypes, which may reflect distinct pathogenic pathways, can provide novel neurobiological insights and enhance our understanding of the molecular mechanisms underlying TBI pathophysiology (Table 1) These findings have major implications for human studies. First, they provided insight into the pathobiology of TBI-induced coagulopathy and identified/defined potential therapeutic target to prevent or attenuate this condition. Furthermore, they indicate that BDMVs released from injured brain could be used as early predictive markers -treatment-response modifiers -and to monitor the biochemical effect (downstream effects on pathogenic mechanisms) of drugs, thus, suggesting that they might be adopted as valuable theragnostic markers in clinical trials.
As yet, the factors leading to the generation of procoagulant MPs after TBI are unclear.
Whereas it is well-know that the brain is enriched in procoagulant anionic phospholipids, no correlation has been established between the extent or type of brain trauma and the release of procoagulant MPs [41] . In the future, it will be crucial to understand how specific injury and patient characteristics contribute to the MPs phenotype which, in turn, can initiate, modulate or exacerbate molecular mechanisms underlying TBI pathophysiology and recovery.
Understanding such pathways might be used to make decisions about prognosis and timely treatment planning, stopping the pathological processes even before clinical symptoms occur.
Inflammation
EVs have also been implicated in inflammation. Recent experimental and human studies have A c c e p t e d M a n u s c r i p t
Possible role of exosomes in the treatment of traumatic brain injury
The Taken together, these studies demonstrate that cell-free exosome-based therapy appears a promising approach and may represent a major leap forward in our understanding of the mechanisms of pathophysiology and neuroprotection in TBI.
However, investigators still need to optimize exosome production and quality control, including definition of the producer cells and their physiological status, and refinement of methods to purify and characterize exosomes. Furthermore, dosing, timing, toxicity and mechanisms of MSC exosome treatment have to be thoroughly examined and addressed. These fundamental issues must be overcome before moving into clinical trials. Among the currently available methods for isolation and purification, differential centrifugation which involves several centrifugation and ultracentrifugation steps is the most commonly used (see Table 1 ). Nonetheless, protocols can vary across laboratories and this lack of standardization is a source of variability leading to inconsistencies in recovery of EVs and, A c c e p t e d M a n u s c r i p t 
Extracellular vesicles -biofluids analytical challenges

Expert commentary
This review brings together information and provides a comprehensive overview on the role of extracellular vesicles in TBI. The novel insights highlight the mounting interest and enhanced understanding of EVs suggesting and supporting that this novel class/family of markers could yield transformative approaches to TBI diagnosis, characterization and treatment. The particularly exciting prospect is that besides the potential to sort out patient and injury variability, EVs can unveil pathophysiological processes initiated by TBI that can lead to secondary and long term complications, and therefore, allowing for predictive, personalized, and even preemptive therapeutic strategy and bringing personalized medicine to patients.
However, a series of critical issues still needs to be addressed to permit the deployment of EVs as brain injury biomarkers in the clinic. With respect to "analytical performance", important technical considerations will concern the development of analytically validated methods capable Nonetheless, conducting large-scale studies and addressing the effect of potential confounding factors (e.g. gender, age, race, etc.) will be instrumental to confidently interpret levels and changes in the circulating EVs and enable the successful implementation in clinical practice and diagnosis of disease. Germane to this, normative reference ranges in large cohorts representative of different healthy populations must be generated.
Finally, to achieve qualification and regulatory acceptance and, thus, be broadly used by the medical community, evidentiary standards will be needed to evaluate and define clinical utility of specific EV populations within specific context of use (COU) and to assess the added beyond current clinical practice while providing new methodological approaches for their integration and combination with other types of clinical and molecular data.
Five-year view
Building on these interesting and exciting data, the EV research field has now become very active and, undoubtedly, will attract a broader interest and support over the next five years.
Crucial next steps of this future work will imply establishing standardized rigorous protocols, building more reliable analytical platforms, as well as conducting well-designed and properly powered studies for validation purposes and to explore potential clinical use. Sharing emerging data and samples will be also imperative for accelerating progress toward the adoption of EVs in clinical practice.
However, these complex tasks and challenges cannot be addressed by a single entity. Specific programs fostering strategic public-private collaborations and multi-party consortia, leading to dialog and cross-fertilization, and allowing exchange and pooling of expertise, knowledge and resources, will be pivotal in achieving the substantial leaps forward in EVs development and truly making an impact on widespread medical practice.
Key issues
• EVs are an emerging class of biomarkers consisting of a heterogeneous group of membrane vesicles, including exosomes and microvesicles, which have key roles in cell signaling and intercellular communication. The analysis of their content permits to track their parental cells and determine their function as well as the cells they will interact with.
• EVs are released by brain cells and their production is enhanced following TBI. Mounting evidence suggests that they play a casual role in the pathogenesis and recovery of acute and chronic TBI, promoting TBI-associated coagulopathy and neuroinflammation and potentially propagating neurodegeneration on the one hand, while participating in immune modulation and neural repair on the other.
• The characterization of brain-derived EVs leaking into the circulation may provide crucial information and shed light on the injury and recovery patterns cell injury, leading to the identification of specific TBI phenotypes/signatures and helping sorting out patient and injury variability.
• Because of their subcellular size, ability to cross the blood-brain barrier, stability and the link with brain damage and pathophysiological mechanisms of TBI, specific selected populations of exosomes and MVs/MPs could also serve as predictive biomarkers, as well as therapeutic targets and delivery systems of neuroprotective compounds, opening a new frontier in the field of neuroprotection.
• Rigorous standardization, validation process and reproducibility, as well as more refined and accurate analytical techniques are essential to ensure the successful translation of EVs as TBI biomarkers to bedside.
• EVs yields a transformative potential in the context of TBI diagnosis and treatment, offering novel approaches to improve characterization and classification of TBI, and to develop more targeted personalized, and even preemptive therapeutic strategies towards precision medicine practice.
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